These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 7162468

  • 41. Ara-C differentially affects multiprotein forms of human cell DNA polymerase.
    Wills PW, Hickey R, Malkas L.
    Cancer Chemother Pharmacol; 2000; 46(3):193-203. PubMed ID: 11021736
    [Abstract] [Full Text] [Related]

  • 42. Effects of 1-beta-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase beta.
    Ohno Y, Spriggs D, Matsukage A, Ohno T, Kufe D.
    Cancer Res; 1988 Mar 15; 48(6):1494-8. PubMed ID: 3345522
    [Abstract] [Full Text] [Related]

  • 43. Inhibition of DNA replicon initiation by 4-nitroquinoline 1-oxide, adriamycin, and ethyleneimine.
    Painter RB.
    Cancer Res; 1978 Dec 15; 38(12):4445-9. PubMed ID: 102423
    [Abstract] [Full Text] [Related]

  • 44. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Abe I, Saito S, Hori K, Suzuki M, Sato H.
    Cancer Res; 1982 Jul 15; 42(7):2846-51. PubMed ID: 7083175
    [Abstract] [Full Text] [Related]

  • 45. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
    Grant S, Bhalla K, Rauscher F, Cadman E.
    Cancer Res; 1983 Nov 15; 43(11):5093-100. PubMed ID: 6577943
    [Abstract] [Full Text] [Related]

  • 46. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA.
    Major PP, Egan EM, Beardsley GP, Minden MD, Kufe DW.
    Proc Natl Acad Sci U S A; 1981 May 15; 78(5):3235-9. PubMed ID: 6942429
    [Abstract] [Full Text] [Related]

  • 47. Inhibition of DNA synthesis in mammalian cells by daunomycin. Preferential inhibition of replicon initiation at low concentrations.
    Schellinx JA, Dijkwel PA, Wanka F.
    Eur J Biochem; 1979 Dec 17; 102(2):409-16. PubMed ID: 527586
    [Abstract] [Full Text] [Related]

  • 48. Synergistic interaction between etoposide and 1-beta-D-arabinofuranosylcytosine.
    Ohkubo T, Hori H, Higashigawa M, Kawasaki H, Kamiya H, Sakurai M, Kagawa Y, Kakito E, Sumida K, Ooi K.
    Adv Exp Med Biol; 1989 Dec 17; 253B():355-62. PubMed ID: 2610123
    [Abstract] [Full Text] [Related]

  • 49. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
    Danhauser LL, Rustum YM.
    Cancer Res; 1985 May 17; 45(5):2002-7. PubMed ID: 3986756
    [Abstract] [Full Text] [Related]

  • 50. Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors.
    Grant S, Rauscher F, Cadman E.
    Cancer Res; 1982 Oct 17; 42(10):4007-13. PubMed ID: 6955007
    [Abstract] [Full Text] [Related]

  • 51. Time sequential expression of markers of apoptosis induced by 1-beta-D-arabinofuranosylcytosine in human T-lymphoblastic leukemia CCRF-CEM cells.
    Badran A, Iwasaki H, Wano Y, Kishi S, Ueda T.
    Anticancer Res; 2001 Oct 17; 21(3B):1987-95. PubMed ID: 11497288
    [Abstract] [Full Text] [Related]

  • 52. [Caffeine inactivation of mammalian cells in the S phase of the mitotic cycle due to anomalous replicon initiation during the inhibition of the elongation of replicating DNA].
    Filatov MV, Sheĭkna TA.
    Tsitologiia; 1984 Oct 17; 26(10):1208-12. PubMed ID: 6515721
    [Abstract] [Full Text] [Related]

  • 53. Studies on the mechanism of action of cytosine arabinoside.
    Kufe DW, Major PP.
    Med Pediatr Oncol; 1982 Oct 17; 10 Suppl 1():49-67. PubMed ID: 6761569
    [Abstract] [Full Text] [Related]

  • 54. Mode of inhibition of DNA replication in neocarzinostatin-treated HeLa cells.
    Hatayama T, Yukioka M.
    Biochim Biophys Acta; 1983 Aug 02; 740(3):291-9. PubMed ID: 6223664
    [Abstract] [Full Text] [Related]

  • 55. Cell growth state determines susceptibility of repair DNA synthesis to inhibition by hydroxyurea and 1-beta-D-arabinofuranosylcytosine.
    Mullinger AM, Collins AR, Johnson RT.
    Carcinogenesis; 1983 Aug 02; 4(8):1039-43. PubMed ID: 6872149
    [Abstract] [Full Text] [Related]

  • 56. Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-beta-D-arabinofuranosylcytosine.
    Horber DH, von Ballmoos P, Schott H, Schwendener RA.
    Br J Cancer; 1995 Nov 02; 72(5):1067-73. PubMed ID: 7577448
    [Abstract] [Full Text] [Related]

  • 57. Biochemical pharmacology of cytosine arabinoside.
    Momparler RL.
    Med Pediatr Oncol; 1982 Nov 02; 10 Suppl 1():45-8. PubMed ID: 7162466
    [Abstract] [Full Text] [Related]

  • 58. Membrane affinity and metabolism of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine into cultured KB cells.
    Tsuruo T, Iida H, Hori K, Tsukagoshi S, Sakurai Y.
    Cancer Res; 1981 Nov 02; 41(11 Pt 1):4484-8. PubMed ID: 7306971
    [Abstract] [Full Text] [Related]

  • 59. Cellular and clinical pharmacology of low-dose ara-C.
    Kufe DW, Griffin JD, Spriggs DR.
    Semin Oncol; 1985 Jun 02; 12(2 Suppl 3):200-7. PubMed ID: 3925558
    [Abstract] [Full Text] [Related]

  • 60. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells.
    Lauzon GJ, Paran JH, Paterson AR.
    Cancer Res; 1978 Jun 02; 38(6):1723-9. PubMed ID: 274174
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.